Related Announcements

PAR-22-049 - Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

This Notice corrects the expiration date for Funding Opportunity Announcement (FOA) PAR-22-049, "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)".

The following modification has been made to PAR-22-049 to reflect the corrected expiration date:

Currently Reads:

Part 1. Overview Information

Key Dates

Expiration Date: September 14, 2023

Modified to Read (change shown in bold italics):

Part 1. Overview Information

Key Dates

Expiration Date: September 14, 2024

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Lokesh Agrawal, PhD
National Cancer Institute (NCI)
Telephone:240-276-5718
Email: [email protected]

Abhi Rao, PhD
National Cancer Institute (NCI)
Telephone: 240-276-5715
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]

Financial/Grants Management Contact(s)

Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: [email protected]